Search PubMed⌕ Search

Biomedical subjects

H G Bone

Publications and source records attributed to H G Bone.

64 records · Page 4Linked to original sources
PubMed1980

Distribution of immunoreactive calcitonin in the rat pituitary gland.

Immunohistochemical (immunoperoxidase) studies were performed on 478 sections from 97 rat pituitary glands with rabbit antisera to unconjugated human synthetic calcitonin beta-endorphin, and/or ACTH-(17--39). Calcitonin-positive cells were present in a majority of the anterior lobes studied, whereas they were present in only a minority of the intermediate lobes. Calcitonin-positive cells were also present in chronically thyroidectomized animals. Beta-Endorphin-positive cells were uniformly present in the intermediate lobes as were the ACTH-positive cells. In the anterior pituitary lobes, beta-endorphin-positive cells were more populous than the ACTH-positive cells, and in general, there was a dissociation of the cellular elements containing beta-endorphin, ACTH, and calcitonin. Although it remains possible that there is calcitonin-like immunoreactivity within a precursor molecule that is differentially processed by pituitary cells, these studies are more consistent with the view that immunoreactive calcitonin is present in pituitary cells which are not as yet precisely and consistently related to any identifiable population of hormone-producing cells.

Animals↗
PubMed1980

Immunohistological studies of medullary thyroid carcinoma and C cell hyperplasia.

A series of 59 thyroidal C cell neoplasms was studied by immunoperoxidase histology. These neoplasms included human medullary thyroid carcinoma and C cell hyperplasia and rat medullary thyroid carcinoma. In addition to calcitonin, the tumors were studied by immunohistology for the presence of beta-endorphin, ACTH, and somatostain. All but one of the neoplasms were positive for calcitonin, 25 of 31 were positive for beta-endorphin, 12 of 18 were positive for ACTH, and 9 of 19 were positive for somatostatin immunoreactivity. Many tissues contained all 4 peptides, and in some sections these peptide immunoreactivities seemed to be present in the same cells. These studies suggest that there is a relationship in these tumors among the 4 peptides studied, but the basis of this relationship is not clear.

Adrenocorticotropic Hormone↗
PubMed1979

Treatment of calcium urolithiasis with diphosphonate: efficacy and hazards.

The effect of treatment of renal stone formation with 5 to 20 mg./kg. per day oral disodium ethane-1-hydroxy-1,1-diphosphonate for up to 30 months was examined in 12 patients with active renal (calcium) stone disease. The over-all incidence of stone passage decreased from 17.8 stones per year per patient before treatment to 7.7 stones per year per patient during therapy. Of the 12 patients 7 passed fewer stones or no stones during treatment. However, the incidence of stone passage was not changed substantially by disodium ethane-1-hydroxy-1,1-diphosphonate in 5 patients. Symptoms of muscle weakness and pain in the back, hips and shoulders occurred in 3 patients during treatment, 2 patients had an increase in serum alkaline phosphatase and 1 patient had a decrease in bone density. Although disodium ethane-1-hydroxy-1,1-diphosphonate may be clinically useful to manage calcium urolithasis in certain patients its over-all use is limited because of its ineffectiveness in some patients and owing to its potential to induce osteomalacia.

Administration, Oral↗
PubMed1979

Effect of parathyroidectomy on serum 1 alpha,25-dihydroxyvitamin D and intestinal calcium absorption in primary hyperparathyroidism.

Serum concentration of 1 alpha,25-dihydroxyvitamin D [1,25(OH)2D] and intestinal absorption were measured before and after parathyroidectomy in 11 patients with primary hyperparathyroidism. Serum 1,25(OH)2D was high preoperatively (P less than 0.001) and normal postoperatively. Ca absorption was elevated preoperatively (P less than 0.001) and decreased significantly after parathyroidectomy (P less than 0.001). However, 5 of 11 patients had a persistent hyperabsorption of Ca postoperatively, despite normal serum 1,25(OH)2D. The results suggest that factors other than 1,25(OH)2D contribute to the maintenance of high intestinal Ca absorption in hyperparathyroid patients in the postoperative state.

Adult↗
PubMed1978

Demonstration by immunoperoxidase histochemistry of calcitonin in the anterior lobe of the rat pituitary.

We have demonstrated by a specific immunoperoxidase procedure the presence of calcitonin-containing cells in the rat pituitary gland. These cells are widely distributed throughout the anterior lobe and seem to constitute the entire population of cells of the intermediate lobe. No such cells were seen in the posterior lobe. The presence of calcitonin-containing cells in the pituitary provides novel implications about the physiological significance of this hormone.

Animals↗
PubMed1977

Diagnosis of hyperparathyroidism.

States of hypersecretion of PTH may occur primarily, or in response to other physiologic abnormalities. Primary hyperparathyroidism must be considered in the differential diagnosis of hypercalcemia, nephrolithiasis, metabolic bone disease, and pancreatitis and peptic-ulcer disease. The clinical manifestations of this disease have become more subtle with improved detection. The serum calcium level is almost always elevated, and when it it accompanied by relatively high serum PTH levels or increased urinary cAMP excretion, the diagnosis is usually secure. Findings of hypophosphatemia, decreased renal tubular reabsorption of phosphorus, hypercalciuria, and characteristic roentgenographic changes support the diagnosis of hyperparathyroidism, but are not prerequisites for that diagnosis. Most cases will come to operation, and experienced intraoperative assessment is necessary for the correct distinction between multiglandular disease and that involving only a single gland. We expect that a clearer understanding of the histopathologic features of these diseases, and improvement in the methods for measurement of PTH will be the main areas of advancement in the diagnosis of hyperparathyroidism in the next few years.

Bone Diseases↗
PubMedDate not supplied

Enhancement of axillary brachial plexus block anesthesia by coadministration of neostigmine.

BACKGROUND AND OBJECTIVES: The acetylcholinesterase inhibitor neostigmine has shown peripherally mediated analgesic action in recent preclinical and clinical studies. The present study investigates the effectiveness of adding neostigmine to a local anesthetic, mepivacaine, in patients receiving axillary brachial plexus block for upper extremity surgery. METHODS: In a double-blind, randomized study 34 patients were assigned to the treatment group: Neostigmine (NM) (500 microg) + mepivacaine (M) (500 mg) (NM, n = 17) as drugs for the plexus block, or to control group: mepivacaine (500 mg) + saline (0.9%, 1 mL) (M, n = 17). RESULTS: The onset and duration of sensory and motor block was similar in both groups. Patients receiving NM had significantly lower pain ratings [visual analogue scores (VAS): 14.7 +/- 9.9 vs 32.4 +/-23.5; P < .05] 24 hours after surgery, and a lower number of patients in the NM group needed supplemental analgesics during the first 24 hours postoperatively. No adverse events were recorded for either group. CONCLUSIONS: Peripherally administered neostigmine improves postoperative analgesia in axillary brachial plexus block.

Adjuvants, Anesthesia↗
PubMedDate not supplied

Effects of an L-selectin antibody on the pulmonary and systemic manifestations of severe smoke inhalation injuries in sheep.

Sheep were treated with either lymphocyte adhesion molecule (LAM)1-3, an antibody against L-selectin, (40 mg 1 hour before smoke inhalation and 35 mg 24 hours after smoke inhalation; n = 6) or equivalent volumes of 0.9% saline solution (n = 6). After the smoke inhalation injuries, the PaO2/FIO2 ratio declined in both groups until 40 hours after the injuries, when a trend toward improvement was noted in the group that received LAM1-3. Lung lymph flow increased in both groups until 36 hours after the smoke inhalation injuries and then significantly decreased in the group that received LAM1-3. Forty-eight hours after the smoke inhalation injuries, there was a significant decrease in the ratio of wet-dry lung weight and in preservation of the reflection coefficient in the group that received LAM1-3 (P < .05). Histopathologic examination showed no differences between the groups in the pulmonary morphology associated with smoke inhalation. A reduction in splanchnic blood flow was noted in the control group (P < .05); this reduction was attenuated by treatment with LAM1-3. The delayed pulmonary effects and improved splanchnic blood flow suggested that LAM1-3 attenuated the development of a systemically induced secondary lung injury rather than of the primary lung injury associated with smoke inhalation.

Animals↗
PubMedDate not supplied

The future of osteoporosis diagnosis and therapy.

Advancing the diagnosis and treatment of osteoporosis will require progress on several fronts: we must overcome the current widespread failure to fully employ the means already at our disposal for the evaluation, prevention and treatment of osteoporosis. Diagnostic testing must become more effective at characterizing the bone and mineral metabolism of the individual patient. Testing must do far more than identify candidates for treatment; it must permit monitoring of the response to therapy or progression of disease. New therapies should have well-characterized, very specific physiological effects. It is critical that they do not produce adverse effects on the bone remodeling mechanism. Gaps in our understanding of the relationships between the mechanical functions of the skeleton and the biology of bone tissue must be filled in order to provide a basis for evaluation and treatment of the skeleton as an integrated organ system.

Biomechanical Phenomena↗